ReviewEuropean thyroid journal2026
Brain fatigue in Graves' disease: symptoms and presentation of a possible mechanism at the cellular level.
Review in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue in patients with Graves' disease (GD) is characterized by a profound lack of mental energy that affects daily functioning, including work. This symptom is particularly prominent in the early stages of the disease, affecting more than 50% of patients, but in some cases, it persists even after successful endocrinological treatment and restoration of euthyroidism. Individuals with persistent fatigue often seek support. Because this tiredness originates in the brain, we refer to it as brain fatigue. It is accompanied by a cluster of interconnected symptoms as cognitive, sensory, and emotional, which we define collectively as brain fatigue syndrome (BFS). BFS is marked by reduced perceived energy levels and associated impairments across multiple domains. The aim of this paper is to improve the understanding and identification of BFS in GD and to propose potential treatment options. We also propose a hypothesis, supported by robust preclinical evidence, that the inflammatory response in this autoimmune disorder may lead to astrocyte dysfunction, impairing neuronal signaling for multiple neurotransmitters. This could reduce the efficiency of brain information processing, increase activation of larger brain areas, and diminish glucose uptake from the bloodstream. Such changes may result in widespread brain dysfunction, culminating in an energy crisis that manifests as profound fatigue and cognitive, sensory, and emotional impairments. However, this hypothesis needs to be tested in humans, particularly regarding the persistence of brain fatigue in GD after normalization of thyroid hormone levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.